🇺🇸 FDA
Pipeline program

BDP HFA Nasal Aerosol

BDP-AR-101

Phase 1 small_molecule completed

Quick answer

BDP HFA Nasal Aerosol for Allergic Rhinitis is a Phase 1 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Teva Pharma GmbH
Indication
Allergic Rhinitis
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials